Latest Breaking News On - Conjugated antisense - Page 4 : comparemela.com

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeksData further strengthen eplontersen s.

Eugene schneiderDrug administrationExchange commissionIonis pharmaceuticals incIonis pharmaceuticalsPrnewswire ionis pharmaceuticals nasdaqTopline phaseNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyNew drug applicationOrphan drug designationConjugated antisense

Ionis announces positive donidalorsen late-stage clinical progress in HAE

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive clinical progress with donidalorsen, its late-stage investigational.

Richards gearyIonis pharmaceuticals incIonis pharmaceuticalsExchange commissionPrnewswire ionis pharmaceuticals incAngioedema qualityLife questionnaireHereditary angioedemaConjugated antisense

Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN

/PRNewswire/ Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform.

United statesSami khellaEugene schneiderAmerican academy of neurologyDrug administrationUniversity of pennsylvania school medicinePrnewswire ionis pharmaceuticals incAmerican academy of neurology annual meetingPenn presbyterian medical centerExchange commissionIonis pharmaceuticalsInternational symposium on amyloidosisIonis pharmaceuticals incAmerican academyAnnual meetingNeuropathy impairment score

Ionis and AstraZeneca Report Positive Topline 66-Week Results of Eplontersen Phase 3 Study for Patients with ATTRv-PN

Ionis and AstraZeneca Report Positive Topline 66-Week Results of Eplontersen Phase 3 Study for Patients with ATTRv-PN
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesEugene schneiderAmerican academy of neurology annual meetingDrug administrationIonis pharmaceuticalsRare dailyNeuropathy impairment scoreNorfolk qualityLife questionnaire diabetic neuropathyAmerican academyNeurology annual meetingConjugated antisenseMene pangalosNew drug applicationOrphan drug

Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

/PRNewswire/ Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug.

Eugene schneiderInternational symposium on amyloidosisIonis pharmaceuticals incDrug administrationPrnewswire ionis pharmaceuticals nasdaqExchange commissionIonis pharmaceuticalsOrphan drug designationNew drug applicationPrescription drug user fee actInternational symposiumConjugated antisense